Fresenius Medical Care Corporation
$ 24.44
-0.08%
13 Feb - close price
- Market Cap 14,280,236,000 USD
- Current Price $ 24.44
- High / Low $ 24.61 / 24.32
- Stock P/E 16.87
- Book Value 53.05
- EPS 1.45
- Next Earning Report 2026-02-24
- Dividend Per Share $1.44
- Dividend Yield 3.33 %
- Next Dividend Date -
- ROA 0.03 %
- ROE 0.06 %
- 52 Week High 29.71
- 52 Week Low 20.95
About
Fresenius Medical Care AG & Co. KGaA provides dialysis care and related dialysis care services in Germany, North America and internationally. The company is headquartered in Bad Homburg, Germany.
Analyst Target Price
$28.21
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-04 | 2025-08-05 | 2025-05-05 | 2025-02-25 | 2024-11-05 | 2024-07-30 | 2024-05-07 | 2024-02-20 | 2023-11-01 | 2023-08-02 | 2023-05-09 | 2023-02-21 |
| Reported EPS | 1.1 | 0.5263 | 0.42 | 0.455 | 0.3988 | 0.24 | 0.41 | 0.44 | 0.28 | 0.3 | 0.26 | 0.43 |
| Estimated EPS | 0.57 | 0.5 | 0.383 | 0.4005 | 0.38 | 0.34 | 0.25 | 0.3 | 0.31 | 0.28 | 0.12 | 0.22 |
| Surprise | 0.53 | 0.0263 | 0.037 | 0.0545 | 0.0188 | -0.1 | 0.16 | 0.14 | -0.03 | 0.02 | 0.14 | 0.21 |
| Surprise Percentage | 92.9825% | 5.26% | 9.6606% | 13.608% | 4.9474% | -29.4118% | 64% | 46.6667% | -9.6774% | 7.1429% | 116.6667% | 95.4545% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-24 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | 0.67 |
| Currency | USD |
Previous Dividend Records
| Jun 2025 | Jun 2024 | Jun 2023 | May 2022 | Jan 1970 | Sep 2020 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | 2025-06-06 | 2024-06-03 | 2023-06-01 | 2022-05-27 | None | 2020-09-11 | None | None | None | None |
| Amount | $0.787104 | $0.634151 | $0.618126 | $0.70929 | $0.833748 | $0.71688 | $0.655083 | $0.632343 | $0.370436 | $0.312726 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: FMS
2026-02-12 08:58:08
ABC Arbitrage SA reduced its holdings in Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) by 91.2% in the third quarter, bringing its stake to 20,211 shares valued at $532,000. Despite this reduction, several other institutional investors increased their positions in the company. Fresenius Medical Care AG & Co. KGaA currently trades at $24.06, with a market capitalization of $13.95 billion, and has an average analyst rating of "Reduce."
2026-02-11 08:27:31
Analysts have issued a consensus "Reduce" recommendation for Fresenius Medical Care AG & Co. KGaA (NYSE:FMS), with three analysts rating the stock a "sell" and five as a "hold". The average 12-month target price is $28.00. Institutional investors have recently adjusted their positions, and the company's stock shows a 50-day simple moving average of $23.15 and a 200-day simple moving average of $24.52.
2026-02-08 12:59:53
Fresenius Medical Care (FMS) has seen its stock gain strongly over the past year despite a recent dip, leading investors to question if it's a defensive gem or a mature company with limited upside. The company's recent earnings showed improved profitability and disciplined capital allocation, with management giving cautious but credible guidance. Analysts hold mixed views, with some seeing value in its predictable cash flow and essential services, while others remain neutral due to regulatory risks and growth constraints in the dialysis market.
2026-01-31 06:29:59
The global specialty medical chairs market reached USD 4.4 billion in 2024 and is projected to grow to USD 7.7 billion by 2033, driven by an aging population, increasing chronic diseases, and a shift towards outpatient care. AI integration is enhancing patient positioning and comfort, while North America holds the largest market share due to high healthcare spending and advanced infrastructure. Key market segments include examination, treatment, and rehabilitation chairs, with hospitals and clinics being primary end-users.
2026-01-31 04:29:12
J.P. Morgan analyst David Adlington has maintained a Buy rating on Fresenius SE & Co. KGaA (0OO9) with a price target of €53.60. This positive sentiment is echoed by UBS, while Goldman Sachs recently downgraded the stock to a Hold. Fresenius SE & Co. KGaA currently has a market capitalization of €27.62 billion and a P/E ratio of 24.41.
2026-01-27 17:57:55
This article reports that FMS stock saw an increase following its Q1 earnings release. The company's earnings surpassed analyst estimates, and its revenues showed a year-over-year increase.
